Abstract

The aim of this study was to present the current state of knowledge on the role of selenium in the treatment of Hashimoto’s disease. In recent years, the number of cases of autoimmune Hashimoto’s thyroiditis – a chronic disease that usually leads to hypothyroidism – has increased. Most patients have elevated levels of anti-TPO antibodies. The presence of these antibodies has an effect on subsequent thyroid damage. So far we have not developed an effective, standard therapy of this disease. However, more attention is being paid to the relationship between supplementation of selenium deficiency and inhibition of production of anti-TPO antibodies in patients with Hashimoto’s thyroiditis. Therefore, selenium supplementation may be an effective option in the treatment of this disease.

References

• 1. Amino N., Tada H., Hidaka Y., Hashimoto K.: Hashimoto’s diseaseand Dr. Hakaru Hashimoto. Endocr. J., 2002; 49: 393-397
  Google Scholar
• 2. Arthur J.R., Bermano G., Mitchell J.H., Hesketh J.: Regulation ofselenoprotein gene expression and thyroid hormone metabolism.Biochem. Soc.Trans., 1996; 24: 384-388
  Google Scholar
• 3. Arthur J.R., Nicol F., Grant E., Beckett G.J.: The effects of seleniumdeficiency on hepatic type I iodothyronine deiodinase and proteindisulphide isomerase assessed by activity measurements and affinitylabelling. Biochem. J., 1991; 274: 297-300
  Google Scholar
• 4. Balázs C.: The effect of selenium therapy on autoimmune thyroiditis.Orv. Hetil., 2008; 149: 1227-1232
  Google Scholar
• 5. Beckett G.J., Arthur JR.: Selenium and endocrine systems. J. Endocrinol.,2005; 184: 455-465
  Google Scholar
• 6. Beckett G.J., Beech S.G., Nicol F., Walker S.W., Arthur J.R.: Speciesdifferences in thyroidal iodothyronine deiodinase expression andthe effect of selenium deficiency on its activity. J. Trace Elem. ElectrolytesHealth Dis., 1993; 7: 123-124
  Google Scholar
• 7. Beech S.G., Walker S.W., Beckett G.J., Arthur J.R., Nicol F., Lee D.:Effect of selenium depletion on thyroidal type-I iodothyronine deiodinaseactivity in isolated human thyrocytes and rat thyroid andliver. Analyst, 1995; 120: 827-831 8 Behne D., Kyriakopoulos A., Meinhold H., Köhrle J.: Identificationof type I iodothyronine 5’-deiodinase as a selenoenzyme. Biochem.Biophys. Res. Commun., 1990; 173: 1143-1149
  Google Scholar
• 8. w tkance gruczołu tarczowego u młodych pacjentów z chorobamiimmunologicznymi i nieimmunologicznymi gruczołu tarczowego.Endokrynol. Pol./Polish J. Endocrinol., 2007; 58: 303-313
  Google Scholar
• 9. Berry M., Banu L., Larsen P.: Type I iodothyronine deiodinaseis a selenocysteine-containing enzyme. Nature, 1991; 349: 438-440
  Google Scholar
• 10. Bonfig W., Gärtner R., Schmidt H.: Selenium supplementationdoes not decrease thyroid peroxidase antibody concentration inchildren and adolescents with autoimmune thyroiditis. ScientificWorldJournal,2010; 10: 990-996
  Google Scholar
• 11. Bossowski A., Czarnocka B., Stasiak-Barmuta A., Bardadin K.,Urban M., Dadan J.: Analiza ekspresji cząsteczek Fas, FasL oraz kaspazy
  Google Scholar
• 12. Chistiakov D.A., Turakulov R.I.: CTLA-4 and its role in autoimmunethyroid disease. J. Mol. Endocrinol., 2003; 31: 21-36
  Google Scholar
• 13. Cho B.Y., Shong Y.K., Lee H.K., Koh C.S., Min H.K., Sohn I.: Roleof blocking TSH receptor antibodies on the development of hypothyroidismand thyroid atrophy in primary myxedema. Korean J.Intern. Med., 1989; 4: 108-117
  Google Scholar
• 14. Contempre B., Denef J.F., Dumont J.E., Many M.C.: Selenium deficiencyaggravates the necrotizing effects of a high iodide dose iniodine deficient rats. Endocrinology, 1993; 132: 1866-1868
  Google Scholar
• 15. Corvilain B., Contempre B., Longombe A.O., Goyens P., GervyDecosterC., Lamy F., Vanderpas J.B., Dumont J.E.: Selenium and thethyroid: how the relationship was established. Am. J. Clin. Nutr.,1993; 57: 244S-248S
  Google Scholar
• 16. Davey J.C., Becker K.B., Schneider M.J., St Germain D.L., GaltonV.A.: Cloning of a cDNA for the type II iodothyronine deiodinase. J.Biol. Chem., 1995; 270: 26786-26789
  Google Scholar
• 17. Duntas L.H., Mantzou E., Koutras D.A.: Effects of a six monthtreatment with selenomethionine in patients with autoimmunethyroiditis. Eur. J. Endocrinol., 2003; 148: 389-393
  Google Scholar
• 18. Dussault J.H., Fisher D.A.: Thyroid function in mothers of hypothyroidnewborns. Obstet. Gynaecol., 1999; 93: 15-20
  Google Scholar
• 19. Erdal M., Sahin M., Hasimi A.: Uckaya G., Kutlu M., Saglam K.:Trace element levels in Hashimoto thyroiditis patients with subclinicalhypothyroidism. Biol. Trace Elem. Res., 2008; 123: 1-7
  Google Scholar
• 20. Falnoga I., Tusek-Znidaric M., Horvat M., Stegnar P.: Mercury,selenium, and cadmium in human autopsy samples from Idrija residentsand mercury mine workers. Environ. Res., 2000; 84: 211-218
  Google Scholar
• 21. Fatourechi V.: Prawda o chorobach autoimmunizacyjnych tarczycy.Medycyna po Dyplomie, 2000; 9: 20-27
  Google Scholar
• 22. Gärtner R., Duntas L.: Effects of selenium supplementation onTPOAb and cytokines in acute autoimmune thyroiditis. Thyroid,2008; 18: 669-670
  Google Scholar
• 23. Gärtner R., Gasnier B.C.: Selenium in the treatment of autoimmunethyroiditis. Biofactors, 2003; 19: 165-170
  Google Scholar
• 24. Gärtner R., Gasnier B.C., Dietrich J.W., Krebs B., Angstwurm M.W.:Selenium supplementation in patients with autoimmune thyroiditisdecreases thyroid peroxidase antibodies concentrations. J. Clin.Endocrinol. Metab., 2002; 87: 1687-1691
  Google Scholar
• 25. Karanikas G., Dudczak R., Willheim M.: Author’s Response toLetters to the Editor Concerning ‘‘No Immunological Benefit of Seleniumin Consecutive Patients with Autoimmune Thyroiditis’’. Thyroid,2008; 18: 673-674
  Google Scholar
• 26. Karanikas G., Schuetz M., Kontur S., Duan H., Kommata S.,Schoen R., Antoni A., Kletter K., Dudczak R., Willheim M.: No immunologicalbenefit of selenium in consecutive patients with autoimmunethyroiditis. Thyroid, 2008; 18: 7-12
  Google Scholar
• 27. Katoh Y., Sato T., Yamamoto Y.: Determination of multielementconcentrations in normal human organs from the Japanese. Biol.Trace Elem. Res., 2002; 90: 57-70
  Google Scholar
• 28. Kawakami A., Eguchi K.: Involvement of apoptotic cell death inautoimmune diseases. Med. Electron Microsc., 2002; 35: 1-8
  Google Scholar
• 29. Köhrle J., Jakob F., Contempré B., Dumont J.E.: Selenium, thethyroid, and the endocrine system. Endocr. Rev., 2005; 26: 944-984
  Google Scholar
• 30. Krysiak R., Okopien B.: The effect of levothyroxine and selenomethionineon lymphocyte and monocyte cytokine release inwomen with Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab.,2011; 96: 2206-2215
  Google Scholar
• 31. Lee J.H., An M.A., Jeon J.S., Song C.U., Shong M., Kim Y.K., RoH.K.: Circulating intercellular adhesion molecule-1 (ICAM-1) in seraof patients with Graves’ disease and Hashimoto disease. Korean J.Intern. Med., 1995; 10: 10-15
  Google Scholar
• 32. Li Y., Shan Z., Teng W., Yu X., Li Y., Fan C., Teng X., Guo R., WangH., Li J., Chen Y., Wang W., Chawinga M., Zhang L., Yang L., Zhao Y.,Hua, T.: Abnormalities of maternal thyroid function during pregnancyaffect neuropsychological development of their children at25-30 months. Clin. Endocrinol., 2010; 72: 825-829
  Google Scholar
• 33. Mazokopakis E.E., Chatzipavlidou V.: Hashimoto’s thyroiditisand the role of selenium. Current concepts. Hell. J. Nucl. Med., 2007,10: 6-8
  Google Scholar
• 34. Mazokopakis E.E., Papadakis J.A., Papadomanolaki M.G., BatistakisAG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES.:Effects of 12 months treatment with L-selenomethionine on serumanti-TPO Levels in patients with Hashimoto’s thyroiditis. Thyroid,2007; 17: 609-612
  Google Scholar
• 35. Mróz-Zawistowska M., Grys I., Lipko A.: Trudności diagnostycznew rozpoznawaniu choroby Hashimoto. Lek. Wojsk., 1998; 11-12:715-718
  Google Scholar
• 36. Nacamulli D., Mian C., Petricca D., Lazzarotto F., Barollo S., PozzaD., Masiero S., Faggian D., Plebani M., Girelli M.E., Mantero F., BetterleC.: Influence of physiological dietary selenium supplementationon the natural course of autoimmune thyroiditis. Clin. Endocrinol.,2010; 73: 535-539
  Google Scholar
• 37. Negro R., Greco G., Mangieri T., Pezzarossa A., Dazzi D., Hassan H.:The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies.J. Clin. Endocrinol. Metab., 2007; 92: 1263-1268
  Google Scholar
• 38. Niedziela M.: Rola peroksydazy tarczycowej w fizjologii i patofizjologiigruczołu tarczowego. Endokrynologia Polska/Polish J.Endocrinol., 2003; 54: 444-449
  Google Scholar
• 39. Papp L.V., Lu J., Holmgren A., Khanna K.K.: From selenium toselenoproteins: synthesis, identity, and their role in human health.Antioxid. Redox Signal., 2007; 9: 775-806
  Google Scholar
• 40. Salvatore D., Bartha T., Harney J.W., Larsen P.R.: Molecular, biologicaland biochemical characterization of the human type 2 selenodeiodinase.Endocrinology, 1996; 137: 3308-3315
  Google Scholar
• 41. Salvatore D., Low S.C., Berry M., Maia A.L., Harney J.W., CroteauW., St Germain D.L., Larsen P.R.: Type 3 iodothyronine deiodinase:cloning, in vitro expression, and functional analysis of the placentalselenoenzyme. J. Clin. Invest., 1995; 96: 2421-2430
  Google Scholar
• 42. Sawin C.T.: The heritage of dr. Hakaru Hashimoto (1881-1934).Endocr. J., 2002; 49: 399-403
  Google Scholar
• 43. Schmidt K.J., Bayer W., Schweizer T., Hewel T.: Selensubstitution– ein therapeutischer Ansatzpunkt bei Schilddrüsenerkrankungen?Vitaminspur., 1998; 13: 33-39
  Google Scholar
• 44. Słowińska-Klencka D., Sporny S., Klencki M., Popowicz B., LewińskiA.: Przewlekłe zapalenie tarczycy – aktualny problem w diagnostycecytologicznej tarczycy. Endokrynol. Pol./Polish J. Endocrinol.,2006; 57: 299-306
  Google Scholar
• 45. Socha K., Dziemianowicz M., Omeljaniuk W.J., Soroczyńska J.,Borawska M.H.: Nawyki żywieniowe a stężenie selenu w surowicyu pacjentów z chorobą Hashimoto. Probl. Hig. Epidemiol., 2012, 93:824-827
  Google Scholar
• 46. Stankowiak-Kulpa H., Sowiński J.: Kliniczne znaczenie mianaautoprzeciwciał anti-TPO w diagnozowaniu chorób tarczycy. NowinyLek., 2000; 69: 606-611
  Google Scholar
• 47. Stassi G., Zeuner A., Di Liberto D., Todaro M., Ricci-Vitiani L.,De Maria R.: Fas-FasL in Hashimoto’s thyroiditis. J. Clin. Immunol.,2001; 21: 19-23
  Google Scholar
• 48. Stęchły T., Kula D., Steinhof K., Jurecka-Lubieniecka B.: PolimorfizmA(-308)G genu TNF i A(49)G genu CTLA-4 w chorobie Hashimoto.Endokr. Pol., 2005; 56: 96-97
  Google Scholar
• 49. Syrenicz A., Syrenicz M., Sworczak K., Garanty-Bogacka B., ZimnickaA., Walczak M.: Choroba Hashimoto i niedoczynność tarczycyw okresie rozrodczym – istotny problem dla kobiety i jej dziecka.Endokrynol. Pol., 2005; 56: 1008-1015
  Google Scholar
• 50. Tiran B., Karpf E., Tiran A.: Age dependency of selenium andcadmium content in human liver, kidney, and thyroid. Arch. Environ.Health, 1995; 50: 242-246
  Google Scholar
• 51. Turker O., Karapolat I.: There is immunological benefit of seleniumtreatment in autoimmune thyroiditis. Thyroid, 2008; 18: 671-672
  Google Scholar
• 52. Turker O., Kumanlioglu K., Karapolat I.: Selenium treatment inautoimmune thyroiditis: 9-month follow-up with variable doses. J.Endocrinol., 2006; 190: 151-156
  Google Scholar
• 53. Zagrodzki P.: Reduktaza tioredoksynowa – nowy cel molekularnychbadań medycznych. Postępy Hig. Med. Dośw., 2002; 56: 155-167
  Google Scholar
• 54. Zagrodzki P., Nicol F., McCoy M.A. Smyth J.A., Kennedy D.G.,Beckett G.J., Arthur J.R.: Iodine deficiency in cattle: compensatorychanges in thyroidal selenoenzymes. Res. Vet. Sci., 1998; 64: 209-211
  Google Scholar
• 55. Zagrodzki P., Ratajczak R.: Selenium supplementation in autoimmunethyroiditis female patient – effects on thyroid and ovarianfunctions (case study). Biol. Trace Elem. Res., 2008; 126: 76-82
  Google Scholar
• 56. Zieleźnik W., Peszel-Barlik M., Sieroń A.: Ultrasonograficzneobrazy we wczesnej fazie choroby Hashimoto. Wiad. Lek., 2001; 53:518-521
  Google Scholar

Full text